Teva Pharmaceutical Industries (TEVA) Current Deferred Tax Assets (2011 - 2016)

Teva Pharmaceutical Industries (TEVA) has reported Current Deferred Tax Assets for 6 consecutive years, with $801.0 million the latest figure, recorded in Q2 2016.

• Quarterly Current Deferred Tax Assets fell 40.75% year-over-year to $801.0 million in Q2 2016, while the trailing twelve-month figure through Jun 2016 was $801.0 million (down 40.75% YoY) and the FY2015 annual result came in at $735.0 million, down 25.98% from the prior year.
• Current Deferred Tax Assets was little changed at $801.0 million in Q2 2016 per TEVA's latest filing, from $805.0 million in the prior quarter.
• Over the last five years, Current Deferred Tax Assets for TEVA reached as high as $1.4 billion in Q2 2015 and fell as low as $735.0 million in Q4 2015.
• A 5-year average of $1.0 billion and a median of $1.0 billion in 2013 frame the typical range for Current Deferred Tax Assets.
• Annual changes were most pronounced in 2015 — Current Deferred Tax Assets increased 26.83% — and 2016, when it sank 40.75%.
• Year by year, Current Deferred Tax Assets stood at $1.1 billion in 2012, then dropped by 5.08% to $1.1 billion in 2013, then retreated by 8.39% to $993.0 million in 2014, then retreated by 25.98% to $735.0 million in 2015, then rose by 8.98% to $801.0 million in 2016.
• According to Business Quant data, Current Deferred Tax Assets over the past three periods registered $801.0 million, $805.0 million, and $735.0 million for Q2 2016, Q1 2016, and Q4 2015 respectively.